Diagnosis and management of Graves' disease

CMAJ. Canadian Medical Association Journal

Volumn 168, Issue 5, 2003, Pages 575-585

  Ginsberg, Jody ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; AMIODARONE; ANTIRETROVIRUS AGENT; ANTITHYROID AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DEXAMETHASONE; ESMOLOL; GLUCOCORTICOID; HYDROCORTISONE; IODINATED CONTRAST MEDIUM; IODINE; IOPANOIC ACID; IOPODIC ACID; LIOTHYRONINE; LITHIUM; LUGOL; METOPROLOL; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROPRANOLOL; PROPYLTHIOURACIL; RADIOACTIVE IODINE; SODIUM IODIDE; THIAMAZOLE; THYROTROPIN RECEPTOR; THYROXINE;

AGRANULOCYTOSIS; APLASTIC ANEMIA; AUTOIMMUNE DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; GRAVES DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTHYROIDISM; LIVER TOXICITY; MULTIPLE SCLEROSIS; PATHOGENESIS; PREGNANCY; REVIEW; SKIN DISEASE; THYROID CRISIS; THYROID DISEASE; THYROIDECTOMY; TOXIC HEPATITIS; TREATMENT INDICATION; TREATMENT PLANNING; VASCULITIS;

EID: 0037418362     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr Rev 1998;19:673-716.
2. McLachlan SM, Pegg CA, Atherton C, Middleton SL, Clark F, Rees Smith B. TSH receptor antibody synthesis by thyroid lymphocytes. Clin Endocrinol 1986;24:223-30.
3. Weetman AP. Graves' disease. N Engl J Med 2000;343:1236-48.
4. Volpe R. The immunoregulatory disturbance in autoimmune thyroid disease. Autoimmunity 1988;2:55-72.
5. Tamai H, Kasagi K, Takaichi Y, Takamatsu J, Komaki G, Matsubayashi S, et al. Development of spontaneous hypothyroidism in patients with Graves' disease treated with anti-thyroidal drugs: clinical, immunological and histological findings in 26 patients. J Clin Endocrinol Metab 1989;69:49-53.
6. Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy. N Engl J Med 1993;329:1468-75.
7. Wall JR. Graves' disease is a multi-system autoimmune disorder in which extraocular muscle damage and connective tissue inflammation are variable features. Thyroid 2002;12:35-6.
8. Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993;14:747-93.
9. Geffner DL, Hershman JM. β-Adrenergic blockade for the treatment of hyperthyroidism. Am J Med 1992;93:61-8.
10. Nordyke RA, Gilbert FI Jr, Harada AS. Graves' disease: influence of age on clinical findings. Arch Intern Med 1988;148:626-31.
11. Thomas FB, Mazzaferri EL, Skillman TG. Apathetic thyrotoxicosis: a distinctive clinical and laboratory entity. Ann Intern Med 1970;72:679-85.
12. Nijs HG, Radder JK, Frolich M, Krans HMJ. Increased insulin action and clearance in hyperthyroid newly diagnosed IDDM patient: restoration to normal with anti-thyroid treatment. Diabetes Care 1989;12:319-24.
13. Boyages SC. The neuromuscular system and brain in thyrotoxicosis. In: Braverman LE, Utiger RD, editors. Werner and Ingbar's the thyroid. Philadelphia: Lippincott-Raven; 2000. p. 631-3.
14. Trzepacz PT, Klein I, Roberts M, Greenhouse J, Levey GS. Graves' disease: an analysis of thyroid hormone levels and hyperthyroid signs and symptoms. Am J Med 1989;87:558-61.
15. Wiersinga WM, Prummel MF. An evidence-based approach to the treatment of Graves' ophthalmopathy. Endocrinol Metab Clin North Am 2000;29:297-319.
16. Salvi M, DeChiara F, Gardini E, Minelli R, Bianconi L, Alinovi A, et al. Echographic diagnosis of pretibial myxedema in patients with autoimmune thyroid disease. Eur J Endocrinol 1994;131:113-9.
17. Rapoport B, Alsabeh R, Aftergood D, McLachlan SM. Elephantiasic pretibial myxedema: insight into and a hypothesis regarding the pathogenesis of the extrathyroidal manifestations of Graves' disease. Thyroid 2000;10:685-92.
18. Becker DV, Bigos ST, Gaitan E, Morris JC, Rallison ML, Spencer CA, et al. Optimal use of blood tests for assessment of thyroid function. JAMA 1993;269:2736-7.
19. Umena S, Takano T, Iijima T, Hidaka Y, Yagoro A, Takai S, et al. A case of repeated painless thyroiditis followed by Graves' disease. Endocr J 1995;42:821-6.
20. Stocker DJ, Foster SS, Solomon BL, Shriver CD, Burch HB. Thyroid cancer yield in patients with Graves' disease selected for surgery on the basis of cold scintiscan defects. Thyroid 2002;12:305-11.
21. Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves' disease. J Clin Endocrinol Metab 1990;70:1518-24.
22. Cooper DS. Antithyroid drugs. N Engl J Med 1984;311:1353-62.
23. Cooper DS. Which antithyroid drug? Am J Med 1986;80:1165-8.
24. Okamura K, Ikenoue H, Shiroozu A, Sato K, Yoshinari M, Fujishima M. Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves' disease. J Clin Endocrinol Metab 1987;65:719-23.
25. Cooper DS, Goldminz D, Levin AA, Ladenson PW, Daniels GH, Molitch ME, et al. Agranulocytosis associated with anti-thyroid drugs. Ann Intern Med 1983;98:26-9.
26. Shiroozu A, Okamura K, Ikenoue H, Sato K, Nakashima T, Yoshinari M, et al. Treatment of hyperthyroidism with a small single daily dose of methimazole. J Clin Endocrinol Metab 1986;63:125-8.
27. Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y, et al. Anti-thyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 1990;70:675-9.
28. Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Y, et al. Anti-thyroid drugs and Graves' disease - prospective randomized assessment of long-term treatment. Clin Endocrinol 1999;50:127-32.
29. Franklyn JA. The management of hyperthyroidism. N Engl J Med 1994;330:1731-8.
30. Ross DS. Thionamides in the treatment of Graves' disease. UpToDate 2001;9:1.
31. Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, et al. Administration of thyroxine in treated Graves' disease - effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991;324:947-53.
32. Rittmaster RS, Zwicker H, Abbott EC, Douglas R, Givner ML, Gupta MK, et al. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease. J Clin Endocrinol Metab 1996;81:3283-8.
33. McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an anti-thyroid drug. N Engl J Med 1996;334:220-4.
34. Tamai H, Takaichi Y, Morita T, Komaki G, Matsubayashi S, Kuma K, et al. Methimazole-induced agranulocytosis in Japanese patients with Graves' disease. Clin Endocrinol 1989;30:525-30.
35. Graham GD, Burman KD. Radioiodine treatment of Graves' disease. An assessment of its potential risks. Ann Intern Med 1986;105:900-5.
36. Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 1999;353:2111-5.
37. Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 1998;280:347-55.
38. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med 1998;338:712-8.
39. 131I therapy for Graves' disease. N Engl J Med 1984;311:426-32.
40. Farrar JJ, Toft AD. Iodine-131 treatment of hyperthyroidism: current issues. Clin Endocrinol 1991;35:207-12.
41. Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism - prognostic factors for outcome. J Clin Endocrinol Metab 2001;86:3611-7.
42. 131I ablation for Graves' disease. J Clin Endocrinol Metabol 2001;86:3016-21.
43. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992;326:1733-8.
44. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998;338:73-8.
45. Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol 1994;130:494-7.
46. Krassas GE, Heufelder AE. Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts. Eur J Endocrinol 2001;144:311-8.
47. Gorman CA, Garrity JA, Fatourechi V, Bahn RS, Petersen IA, Stafford SL, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 2001;108:1523-34.
48. Lazarus JH, Kokandi A. Thyroid disease in relation to pregnancy: a decade of change. Clin Endocrinol 2000;53:265-78.
49. Wilson LC, Kerr BA, Wilkinson R, Fossard C, Donnai D. Choanal atresia and hypothelia following methimazole exposure in utero: a second report. Am J Med Genet 1998;75:220-2.
50. Momotani N, Noh J, Oyanagi H, Ishikawa N, Ito K. Anti-thyroid drug therapy for Graves' disease during pregnancy. Optimal regimen for fetal thyroid status. N Engl J Med 1986;315:24-8.
51. Momotani N, Yatuashita R, Makino F, Noh JY, Ishikawa N, Ito K. Thyroid function in wholly breast-feeding infants whose mothers take high doses of propylthiouracil. Clin Endocrinol 2000;53:177-81.
52. Wallace C, Couch R, Ginsberg J. Fetal thyrotoxicosis: a case report and recommendations for prediction, diagnosis and treatment. Thyroid 1995;5:125-8.
53. Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am 1993;22:263-77.
54. Toft AD. Clinical practice. Subclinical hyperthyroidism. N Engl J Med 2001;345:512-6.6